Thirty-one patients (27 with acute myeloid leukemia [AMLI, 2 with acute lymphocytic leukemia [ALL], and 2 with acute mixed lineage leukemia [AMLLI) treated with conventional chemotherapy (CHT) and 23 patients (13 AML, 5 ALL, and 5 with chronic myeloid leukemia [CMLI) treated with allogeneic bone marrow transplantation (BMT) were monitored for W1 expression levels in BM and peripheral blood (PB) by reverse transcriptase-polymerase chain reaction over a long-term period (mean, 29 months for CHT and 24 months for BMT). Sixteen of the patients in the CHT group and 3 in the BMT group who had achieved complete remission suffered clinical relapse. In 10 of these patients, W 1 expression that had returned t o normal BM levels the W 1 expression level of K562 cells was defined as 1.0) after complete remission (CR) either gradually or rapidly increased again t o abnormal levels 1 t o 18 months (mean, 7 months) before clinical relapse became apparent. In another 9 patients, W 1 expression never returned t o normal BM levels even after CR and the subsequent relapse was accompanied by a rapid increase in W 1 expression t o levels higher than HE WT1 GENE IS A candidate gene for Wilms tumor, a childhood kidney neoplasm, that is thought to arise as a result of inactivation of both alleles of the WTl gene located at chromosome 1 lp13.'.* The WT1 gene encodes a zinc finger transcription factor with a molecular weight of 52 to 54 kD that features a complex pattern of alternative ~plicing.~ This gene is highly homologous with proteins of the early growth response genes and functions as a potent transcriptional repressor of insulin-like growth factor-I1 (IGF-11): platelet-derived growth factor-A (PDGF-A) chain,5 colony-stimulating factor-l (CSFand IGF-receptor (IGF-R) genes.' It was recently reported that WT1 also functions as a transcriptional activator, suggesting that the WTl is a bifunctional regulator of transcription.',' The WT1 gene has been considered to be a tumor-suppressor gene on the basis of accumulated data.""'
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On the other hand, it was found that the WTl gene had mutated in a human mesothelioma," suggesting its involvement in malignancies other than Wilms tumor. In a previous report, we noted that all human leukemia samples examined expressed the WT1 gene regardless of the disease subtype (acute myeloid leukemia [AML] , acute lymphocytic leukemia [ALL], or chronic myeloid leukemia [CML] ) and that the WT1 expression levels increased in parallel with the progression of clinical stage in CML.14 Furthermore, the WT1 expression levels were found to correlate inversely with the prognosis for acute 1e~kemia.I~ In a more recent report, we observed that WT1 antisense oligomers inhibit the growth of fresh human leukemic cells and leukemic cell lines, but not that of normal colony-forming unit-granulocyte-macrophage (CFU-GM).I5 All these results strongly imply the participation of the WT1 gene in leukemogenesis.
Accurate assessment of minimal residual disease (MRD) in leukemia patients is essential to evaluate the efficacy of treatment regimens, to establish early diagnosis of im- lo-' levels in PB). On the other hand, the remaining 35 patients (15 CHT and 20 BMT) maintained their CR. In 29 of these patients (11 CHT and 18 BMT), W1 expression either gradually or rapidly decreased t o normal BM levels, whereas in the other 6 (4 CHT and 2 BMT), low or very low levels of W1 mRNAs (lo-' t o lo-' in BM and lo-' t o in PB) remain detectable, but without any clinical signs of relapse. A clear correlation was found t o exist between the minimal residual disease (MRD) detected in the paired BM and PB samples for all types of leukemias (AML, ALL, and CML), with MRD in PB being approximately one-tenth of that in BM. W1 quantitation of 168 paired BM and PB samples showed that PB samples were superior t o BM samples for the detection of MRD. We conclude that monitoring of W 1 expression levels in BM and PB makes it possible t o rapidly assess the effectiveness of individual treatment and diagnose clinical relapse in the early stage for all leukemia patients regardless of the presence or absence of tumor-specific DNA markers. 0 1996 by The American Society of Hematology.
pending relapse, and to individualize treatment protocols. WT1 expression levels in leukemic cells are approximately lo3 times higher than in normal bone marrow (BM) and more than lo5 times higher than in peripheral blood (PB) cells.I4 This striking difference in the WTl expression levels between leukemic and normal cells has made it possible to detect MRD at frequencies as low as 1 in lo3 normal BM cells and 1 in 10' normal PB cells. We also showed the possibility of monitoring MRD by means of the serial quantitation of W T 1 expression levels in 9 leukemia patients.14 The most prominent advantage of the diagnosis of MRD by the quantitation of WT1 expression levels is its applicability to almost all cases of leukemia regardless of the subtype or of the presence or absence of DNA markers such as bcr/ ab1,I6-l8 PML/RAR-a,''-** and AML1/ET0.23
For the present study, we followed up MRD by monitoring -n .
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1 o "~w n < 1 0 " H~o o~w n tional chemotherapy [CHT] and 23 BMT) over a long-term period (7 to 124 months; mean, 29 months for CHT and 24 months for BMT). We conclude that the monitoring of WTI expression levels facilitates the assessment of the effectiveness of individual treatment, early diagnosis of relapse, and prediction of prognosis.
MATERIALS AND METHODS
Patients.
This study included patients with leukemia who were admitted between 1984 and 1995 to the institutions specified. Acute leukemia patients were treated with intensive chemotherapy, including daunorubicin, mitoxantrone, 6-mercaptopurine, etoposide, and cytarahine. Patients with CML were treated with interferon-a, hydroxyurea, busulfan, and other anticancer drugs. Allogeneic BM transplantation (BMT) with HLA-identical sibling BM cells was preceded by conditioning therapy with high-dose cyclophosphamide (60 mgkg; 2 doses) and total body irradiation (2 Gy; 6 doses) or by high-dose cyclophosphamide (50 mg/kg; 4 doses) and busulfan (1 mgkg; 16 doses).
Acute leukemia was classified according to the criteria devised by the French-American-British C~r n m i t t e e .~~~~~ AMLL was defined as either leukemia differentiating along a specific lineage but coexpressing other lineage-associated markers or as biphenotypic but not well-differentiated leukemia (CD7+ stem cell leukemia)."
Thirty-one patients (27 AML, 2 ALL, and 2 AMLL) treated with CHT and 23 patients (13 AML, 5 ALL, and 5 CML) treated with BMT were monitored for WTI expression levels in both BM and PB for 7 to 124 months (mean, 29 months for CHT and 24 months for BMT).
Sample preparation. To prepare mononuclear cells from leukemia patients, heparinized PB cells or BM aspirates were mixed with isovolumes of phosphate-buffered saline (PBS) and centrifuged on Ficoll-Isopaque solution (Pharmacia, Uppsala, Sweden). Mononuclear cells were collected by centrifugation and the pellet was washed twice with PBS to remove platelets. Cells ( I X 10' to 1 X IO') were then dissolved in 0.5 mL of solution D (4 molL guanidine thiocyanate, 25 mmol/L sodium citrate, pH 7.0, 0.5% sarcosyl, 0.1 molL 2mercaptoethanol) and stored at -80°C until use.
Reverse transcription-polymerase chain reaction (RT-PCR). Quantitative RT-PCR was performed as described p r e v i~u s l y '~~~' with minor modifications. In brief, 2.0 pg of total RNA from leukemic samples was converted into cDNA in 30 pL of reaction buffer. The level of WTl gene expression in K562 cells was defined as 1 .O. Before the start of the experiments, large amounts of total RNA (>l00 pg) from K562 cells were converted into cDNA, which was then used as the standard throughout our experiments. PCR was performed for 35 cycles with the outer primer to quantitate to levels of WTI expression. To quantitate to IO" levels, PCR was terminated at 27 to 30 cycles. For the quantitation of 10'' to levels, second-round PCR was performed for 10 to 14 cycles using nested internal primers; to quantitate P-actin levels, PCR was performed for 18 cycles. Serial 1 : l O dilutions of standard K562 cDNAs were always amplified simultaneously with leukemic samples. All experiments were performed in duplicate. Standard errors for quantitation of WTI in the same samples were "15% at 10" levels, 225% at 10" levels, and "35% at lo-' levels. RT-PCR for b~r/abl,'"'~ PML/RAR-a,'9'22 and AMLI/ET02' transcripts was performed as described previously.
RESULTS
Assessment of the effectiveness of individuul treatment, early diagnosis of relapse, and prediction of prognosis by monitoring of W T I expression levels. The 31 patients (27 AML, 2 ALL, and 2 AMLL) treated with CHT and the 23 patients (13 AML, 5 ALL, and 5 CML) treated with allogeneic BMT were monitored for the number of blast cells in BM and the WT1 expression levels in both BM and PB (Figs 1 and 2 ).
Sixteen (13 AML, I ALL, and 2 AMLL) of the patients in the CHT group had clinical relapse (Fig 1 A) . These patients were further classified into two groups according to the changes in WTI expression levels in BM: RLI, WTI expression levels either gradually or rapidly increased again to levels of IO-' or more after reduction to normal BM levels; RL2, WT1 expression levels never returned to normal BM levels even after complete remission (CR) and relapsed into leukemia after a short-term CR. In patients no. 5 l , 1 15, and 122, WTI expression at normal BM levels after CR achievement increased to abnormal levels again after the discontinuation of chemotherapy due to its toxicity and this was followed by clinical relapse. WT1 expression in BM increased from normal to abnormal levels as early as 14 (patient no. 51), 18 (patient no. I15), and 8 months (patient no. 122) before clinical relapse. In patient no. 20, intermediate levels (lo-' to lo") of W T I expression continued even after the second CR, which lasted for 3 months; this was followed by clinical relapse and death of the patient. It should be noted that, in all patients with clinical relapse, abnormal levels of WT1 expression in PB continued throughout the clinical course, suggesting the persistence of MRD in PB. (Because at the beginning of this study we did not have the data described in Fig 5 showing that WT1 levels in PB correlatively reflected those in BM, we did not quantitate W T 1 levels in PB. Therefore, we did not have data for many patients on W T 1 levels in PB at the early stage of the clinical course.) Three of the 23 patients who were treated with BMT suffered clinical relapse and were also classified into two groups, R L 1 and RL2, according to the same criteria as those for CHT (Fig 2A) . W T 1 expression for patients no. 242 and 235 changed from PCR negative to positive 2 to 3 months before clinical relapse.
The changes in the W T 1 expression levels for the patients with relapse are shown in Fig 3A for BM and in Fig 4A for PB. In these patients, either rapid or gradual increase in WT1 expression levels occurred in both BM and PB before clinical relapse. These results show that either rapid or gradual increase in WTI expression levels from normal to IO-' levels in BM and to levels in PB (RL1) or a further increase in W T 1 expression over the persistent abnormal levels of WT1 (lU2) suggest clinical relapse in the near future regardless of the modality of treatment (CHT or BMT). The lead 
MRD in PB (CR)
time between positive WTl test and clinical relapse was tabulated in Table 1 .
On the other hand, the patients in continued CR after CHT were classified into two groups according to the changes in WT1 expression levels in BM (Fig 1B) : CR1, WT1 expression decreased to and stayed at normal BM levels after CR; CR2, WTl expression returned to normal BM levels once, but increased again and stayed at low levels to lo-' levels) or W 1 expression never returned to normal BM levels and stayed at low levels even after CR. The patients who are in group CRl at present may deteriorate to CR2 due to a subsequent increase in WT1 expression over normal BM levels. On the other hand, CR2 patients treated with CHT may have to be reclassified as CR1 after more effective therapy such as BMT. In patient no. 164, AMLlETO transcripts were measured simultaneously with WT1. Neither WT1 nor AMLIETO transcripts were detected at 104 and 122 months, suggesting the absence of MRD. In patient no. 179, WT1 expression was abnormal at 35 months, but became undetectable l year later. In patient no. 25, WT1 expression was abnormal in PB at 26 months, but became undetectable 19 months later.
The patients in continuing CR after BMT were similarly classified into two groups, CR1 and CR2, according to the same criteria as those for CHT (Fig 2B) . In patient no. 45 *When W1 levels are more frequently monitored, the lead time t W T 1 levels in PB were not assayed for 4 months between the return to normal levels and subsequent increase to abnormal levels.
will become longer.
tected in PB, but not in BM, 84 months after BMT. In patient no. 120, low levels (10" to IO-') of WTI expression were detected in BM 25 months after BMT, but became undetectable 5 months later. The changes in WT1 expression levels and leukemia-specific bcr/abl transcripts occurred in parallel, confirming that WT1 expression levels reflect MRD. In patients no. 248 and 270, low levels (IO" to lo-') of WTI expression became detectable again 8 and 1 1 months, respectively, after BMT. In patient no. 64, low levels of WT1 expression could still be detected in both BM and PB 28 months after BMT, but became undetectable 7 months later.
Changes in WTl expression levels in the patients in continuing CR are shown in Fig 3B for BM and Fig 4B for PB. For these patients, WT1 expression levels either rapidly or gradually decreased to normal (< or low levels (10" to lo-') in BM and to undetectable (<lo-') or very low (IO-' to to low to levels in PB and then stayed at these levels.
MRD is more sensitively detectable in PB than in BM. Paired BM and PB samples obtained from leukemia patients were quantitated for WT1 expression (Fig 5) . In 33 of 168 paired BM and PB samples (49 AML, 10 ALL, and 10 CML), WT1 expression was within normal BM levels in BM, but abnormal in PB, suggesting the existence of MRD.
On the other hand, in 4 of 168 paired BM and PB samples, WT1 expression was abnormal in BM, but undetectable in PB (Fig 5A) . Therefore, it can be concluded that PB samples are superior to BM samples for the detection of MRD. Similar results were obtained for the paired samples from the patients with AML (Fig 5B), ALL (Fig 5C) , and CML ( Fig  5D) .
Strong correlation between the MRD detected in paired BM and PB samples obtained from leukemia patients. Correlation of WT1 expression levels was examined in paired BM and PB samples of patients expressing both greater than levels in BM and greater than lom5 levels in PB (Fig 5) . Strong correlations (Spearman's correlation coefficient, r > S ) were observed for all types of leukemia (Fig 5B, C, and D) . These results show that the degree of MRD in PB paralleled that in BM, but that MRD detected in PB was approximately 10 times lower than that in BM regardless of the type of leukemia (AML, ALL, or CML).
DISCUSSION
A most important problem in the CHT and BMT for patients with leukemia is the uncertainty as to whether leukemic cells have been totally killed when CR is achieved. If we can monitor leukemia patients for MRD, we may be able to treat individual patients with different protocols based on the extent of MRD. Because the limit of MRD detection is only 1% to 5% for morphologic techniques and as little as 5% to 10% for Southern blot technique, these techniques are not practical for detection of MRD. The sensitivity for MRD detection by fluorescence in situ hybridization (FISH) is no more than 1% because it is limited by the presence of aneuploid (but not leukemic) cells and by certain inherent technical artifacts2* Flow cytometryZ9 for leukemia-associated phenotypes, on the other hand, has a sensitivity of 1 leukemic cell in lo4, but this method is applicable only to leukemia with limited phenotypes. PCR can detect leukemic cells at frequencies as low as 1 in IO5 to IO6 normal cells, but is applicable only to the leukemias that bear tumor-specific DNA markers, including rearranged Ig30 and T-cell receptor genes3' and fused genes such as bcr/abl,'"'' PMURAR-~U,'"~' AML1/ET0,23 and other fused genes.2' Furthermore, detection of MRD by PCR amplification of junctional regions of rearranged Ig and TCR genes can be applied only to B-or T-cell-lineage leukemia and requires cloning and sequencing of the junctional regions before PCR, thus making it too cumbersome for clinical application. Detection of MRD with the aid of PCR amplification of the tumor-specific DNA markers is useful for only 20% to 30% of leukemia patients.
In strong contrast to the techniques described above, detection of MRD by means of the quantitation of WTI gene expression is applicable to all leukemia patients, regardless of the type of leukemia (AML, ALL, or CML) or the presence or absence of tumor-specific DNA markers. Therefore, even in cases in which chromosomal and DNA analyses of fresh leukemic cells were unsuccessful or could not be performed, the WT1 assay can always be used for the detection of MRD. Thus, the WT1 assay has made it possible to rapidly assess the effectiveness of treatment and evaluate the degree of eradication of leukemic cells in individual leukemia patients. The WT1 assay will be beneficial to individualization of treatment protocols for all leukemia patients, although basing treatment on the WT1 assay has not yet been shown to be practically effective. Moreover, the monitoring of WT1 expression levels in BM has made it possible to diagnose relapse l to 18 months (mean, 7 months) before clinical relapse for all leukemia patients. We have recently found that WT1 expression levels per leukemic cell at the time of clinical relapse were approximately 5 times higher than those at the time of diagnosis (manuscript in preparation). This indicates that the sensitivity of MRD detection by quantitation of WT1 expression levels will increase as clinical relapse becomes imminent, thus making it possible to detect MRD with enough sensitivity even in leukemia cases that expressed low levels (lo-' to 10") of the WT1 gene at the time of diagnosis. The following conditions have been identified as indicating that clinical relapse is impending: (1) rapid or gradual increase in WT1 expression to levels of or over after return to normal BM levels at CR (lo-' levels in PB) and (2) the WTl expression stays at levels near or over in BM without return to normal BM levels even after CR. The absolute levels of WT1 that predicts with certainty that a patient will relapse are levels in BM and 10" levels in PB. For the patients with these signs, treatment for relapse should be performed before obvious clinical relapse occurs. Especially in BMT, treatments such as reduction in dosage of cyclosporin A and donor leukocyte transfusion (DLT)32-35 are often effective in the early stages of relapse, when the amount of residual leukemic cells is still small. Therefore, in case of an increase from normal to abnormal BM levels of WT1 expression after BMT, such treatment procedures should be implemented immediately. Thus, monitoring of MRD by the quantitation of WT1 expression levels after BMT is essential. Moreover, when a serial increase in WT1 expression levels is detected in patients treated with CHT, immediate BMT is recommended.
In the present study, the prognosis of the patients in continuing CR whose WT1 expression levels stayed low or very low to lo-* in BM and to in PB) remain unresolved. However, it can be assumed that those whose WT1 expression gradually decreases and returns to normal BM levels can expect to enjoy prolonged disease-free survival, whereas the patients whose WT1 expression gradually or rapidly increases will suffer relapse. Actually, patients no, 51 and 115, who had been classified into group I1 in our previous reportI4 (corresponding to RL1 in this report), relapsed several months after our publication. In patient no. 45 in continuing CR who was treated with BMT, very low 47 In APL, although all-trans retinoic acid induces CR in a high proportion of patients, it rarely eradicates molecular evidence of APL (PMLRAR-a transcripts). However, subsequent chemotherapy can result in changing the RT-PCR assay for PMLIRAR-a to negative. Negative RT-PCR assays are associated with prolonged disease-free survival, whereas a positive RT-PCR assay is highly correlated with subsequent relapse.
In contrast to APL, MRD in CML and AMLlETO-positive AML-M2 is less closely associated with clinical outcome. As for CML, bcdabl transcripts were detected in a significant proportion of longterm remission patients. In AMLUETO-positive AML-M2, persistence of MRD in long-term survivors (5, 8 , and 9 years) was reported, suggesting that complete elimination of AMLIETO-positive leukemic cells is not necessary for the achievement of long-term remission. To determine the clinical significance of persistence of low WTI expression levels, observation of more patients for several years will be needed.
We previously reported that WTI expression was found in all the leukemia patients (45 AML, 22 ALL, 6 AMLL, and 23 CML) we examined and that WTl was identified as a new marker for the diagnosis of MRD.'' Subsequently, Brieger et aI4* reported that the WTl gene was expressed in 79% (41/52) patients with AML and that WTI expression was a possible marker for leukemia blast cells. Their results were basically consistent with those of our preceding report. However, there was an important difference in the incidence of WTl expression in leukemic cells, which can be ascribed to the sensitivity and quantitativity of the PCR used (they could not detect background levels of WTI in normal BM cells).
PB samples were found to be superior to BM samples for the monitoring of MRD because ( l ) the residual leukemic cells flow from BM out into PB in a proportion corresponding to approximately one-tenth of the degree of MRD in BM and (2) the sensitivity for detection of MRD is more than 100 times higher in PB than in BM because of the presence of WTl background levels in BM. Thus, instead of BM samples, aspiration of which is painful for patients and laborious for medical staff, PB samples are sufficient for monitoring MRD.
We have shown that approximately one-tenth of the residual leukemic cells in BM flows out into PB in AML, ALL, and CML. This is fundamentally consistent with the findings that bcr/abl titers in BM samples exceeded those in the corresponding PB samples in all sample pairs by at least 1 log (the mean difference was 1.55 log) in patients with bcdablpositive ALL.49 However, to our knowledge, our study is the first to show clearly the correlative relationship between the MRD in BM and PB in a relatively large sample. Based on these findings, leukemia onset could be diagnosed in PB samples earlier than in BM samples by monitoring WT1 expression levels, making it possible to diagnose leukemia onset very early in persons at high risk for leukemia, ie. those who are accidentally exposed to radioactive rays 01-who have been treated with chemotherapy or radiotherapy for solid tumors. Furthermore, quantitation of WTl expression levels in PB appears to be feasible in medical checkups for leukemia even for healthy individuals.
In conclusion, serial monitoring of WT1 expression levels should be considered indispensable for evaluation of the effectiveness of different therapies and individualization of treatment protocols for leukemia patients. expression of the insulin-like growth factor I receptor gene, IGFIR. 
